Search Results - "Fukuda‐Kurahashi, Y."

  • Showing 1 - 3 results of 3
Refine Results
  1. 1
    P413: THE POTENTIAL USE OF AN ORAL HYPOMETHYLATING AGENT, OR‐2100, AS A COMBINATION THERAPY FOR MYELOID MALIGNANCIES

    P413: THE POTENTIAL USE OF AN ORAL HYPOMETHYLATING AGENT, OR‐2100, AS A COMBINATION THERAPY FOR MYELOID MALIGNANCIES by Kamachi, K., Ureshino, H., Kawasoe, K., Yoshida‐Sakai, N., Yamamoto, Y., Fukuda‐Kurahashi, Y., Kurahashi, Y., Watanabe, T., Kimura, S.

    Published in HemaSphere (23-06-2022)
    Get full text
    Journal Article
    Save to List
    Saved in:
  2. 2
    P1301: BIOLOGICAL SIGNIFICANCE OF UCK2 IN HTLV‐1‐INFECTED CELLS IN ATL LEUKEMOGENESIS AND ACQUIRED RESISTANCE TO AZACITIDINE

    P1301: BIOLOGICAL SIGNIFICANCE OF UCK2 IN HTLV‐1‐INFECTED CELLS IN ATL LEUKEMOGENESIS AND ACQUIRED RESISTANCE TO AZACITIDINE by Watanabe, T., Yamamoto, Y., Kamachi, K., Kurahashi, Y., Yoshida‐Sakai, N., Ureshino, H., Fukuda‐Kurahashi, Y., Nakamura, H., Sueoka, E., Kimura, S.

    Published in HemaSphere (23-06-2022)
    Get full text
    Journal Article
    Save to List
    Saved in:
  3. 3
    PB1701 OR21, A NEWLY ORAL DECITABINE PRODRUG, HAS ANTI‐TUMOR EFFECT AGAISNT MYELODYSPLASTIC SYNDROME AND ACUTE MYELOID LEUKEMIA VIA CELL DIFFERENTIATION INDUCED BY UP‐REGULATION OF CEBPE

    PB1701 OR21, A NEWLY ORAL DECITABINE PRODRUG, HAS ANTI‐TUMOR EFFECT AGAISNT MYELODYSPLASTIC SYNDROME AND ACUTE MYELOID LEUKEMIA VIA CELL DIFFERENTIATION INDUCED BY UP‐REGULATION OF CEBPE by Ureshino, H., Watanabe, T., Kamachi, K., Kurahashi, Y., Fukuda‐Kurahashi, Y., Tohyama, K., Okada, S., Ushijima, T., Kimura, S.

    Published in HemaSphere (01-06-2019)
    “…Background: Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are clonal disorders that originate from abnormal hematopoietic stem cells (HSCs)…”
    Get full text
    Journal Article
    Save to List
    Saved in:

Search Tools: